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Abstract
In the quinazoline antifolate (CB 3717)-induced hyperplastic kidney model, a remarkable increase of ornithine
decarboxylase (ODC) activity was paralleled by a smaller, but highly significant augmentation of the ODC transcript level.
Catecholamine depletion, evoked by reserpine, strongly impaired antifolate-induced ODC expression; the enzyme activity
was almost completely abolished while the mRNA level decreased by 60%. Moreover, under conditions of a depleted
catecholamine pool, kidney enlargement was significantly reduced confirming our earlier reports on the indispensability of
ODC induction for renal hyperplasia (M. Manteuffel-Cymborowska et al., Biochim. Biophys. Acta, 1182 (1993) 133^141[1]).
In normal mouse kidney catecholamines appeared to be inducers of ODC expression. Use of selective agonists of
catecholamine receptors demonstrated the importance of dopamine D2 receptors, and to a lower extent L adrenoreceptors, in
the catecholamine mediation of induction of ODC activity and of ODC mRNA levels.These increases were not abolished by
an antiandrogen, casodex, suggesting that catecholamine control of ODC expression is an androgen receptor-independent
process. The results obtained point to the critical role of renal catecholamines; these biogenic amines are not only involved in
the regulation of ODC expression in normal kidney but are also required for the induction of ODC in hyperplastic kidney
evoked by antifolate and, as shown recently (M. Manteuffel-Cymborowska et al., Biochim. Biophys. Acta, 1356 (1997) 292^
298[2]), in testosterone-induced hypertrophic kidney. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Extracellular signaling substances, acting at their
cell membrane or nuclear receptors, activate speci¢c
transduction pathways and elicit a genomic or non-
genomic response in target cells. Recently, it has
been recognized that diverse signaling pathways do
not act independently but are interconnected with
one another and form a complex network integrated
at di¡erent levels [3^7].
Ornithine decarboxylase (ODC), the ¢rst and rate-
limiting enzyme of polyamine biosynthesis, is an ex-
ample of a protein regulated by various metabolic,
hormonal and neuronal signals [8^13]. The spectac-
ular induction of ODC and its role in mouse kidney
undergoing hypertrophy and hyperplasia evoked by
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the steroid sex hormone, testosterone, and agents
causing renal injury, respectively, has been thor-
oughly studied in our laboratory [1,2,14^17]. Re-
cently, we have documented that catecholamine de-
pletion, evoked by reserpine, dramatically impairs
the testosterone-induced increase of ODC expression
in mouse kidney without a¡ecting its hypertrophy
[2]. This is in agreement with evidence that catechol-
amines are important for the induction of ODC ac-
tivity by steroids in the liver and kidney [18^21].
Thus, both the androgen and catecholamines appear
to be involved in the activation of ODC gene expres-
sion. Androgen and catecholamine signaling path-
ways are likely to integrate at the level of androgen
receptor or transcriptional coactivator(s) [6,7,22].
Androgen receptor is a member of the superfamily
of nuclear receptors acting as transcription factors
activated by cognate lipophilic ligands [23^25] and/
or alternatively by hydrophilic signaling substances
from the cell surface [3^5].
Data about the involvement of catecholamines in
the induction of ODC during renal hyperplasia are
lacking. We approach this problem using our model
of renal hyperplasia in which an anticancer drug, a
quinazoline analogue of folic acid, N10-propargyl-
5,8-dideazafolic acid (CB 3717), is used as an agent
to induce renal damage. This occurs due to its pre-
cipitation at physiological pH in renal tubules [1,14].
The resulting injury of tubular epithelium is followed
by its regenerative hyperplasia. This is characterized
by the augmentation of DNA synthesis and the in-
crease in the activity of two key enzymes of poly-
amine biosynthesis, namely ODC and S-adenosyl-
methionine decarboxylase. The putrescine and
spermidine content is also augmented whereas sper-
mine level is signi¢cantly decreased [1,14].
In this paper we present in vivo data on the inhib-
itory e¡ect of catecholamine depletion evoked by re-
serpine treatment on the CB 3717-induced increase
of ODC activity and ODC mRNA level in hyper-
plastic kidneys. Moreover, we show that the activa-
tion of dopamine receptors and adrenoreceptors
by speci¢c agonists leads to the induction of
ODC expression in the normal mouse kidney. The
signaling pathway likely to be activated in the
injured kidney by the administered antifolate is
discussed.
2. Materials and methods
2.1. Experimental
Swiss female mice, 2.5^3 months old, were injected
with a quinazoline antifolate CB 3717 (300 mg/kg)
dissolved in phosphate-bu¡ered saline (PBS) with ad-
dition of a few drops of 1 M NaOH to ¢nal pH 9^9.5
(controls received PBS only) for 24 h. Reserpine (10
mg/kg) was given 96 h or 1 h before CB 3717. The
dosage (according to literature) and timing of the
applied catecholamine receptor agonists (phenyleph-
rine, [19]; isoproterenol, [19] ; apomorphine, [26] ;
SKF 38393, [27]; quinpirole, [28]), antagonists (phen-
oxybenzamine, [20]; propranolol, [20]; spiroperidol,
[29]; SCH 23390, [30]) and antiandrogen casodex [31]
is shown in the legends of the appropriate ¢gures and
tables. All drugs were injected i.p. with the exception
of casodex which was given s.c. The mice were killed
by cervical dislocation, the kidneys were removed,
weighed, and cut into several pieces.
2.2. Enzyme activity and Northern blot analysis
The kidney pieces were immediately homogenized
in an appropriate bu¡er and further processed for
enzyme activity determinations as previously de-
scribed [16], or were frozen at 370‡C and processed
for ODC mRNA estimation as described [2]. The
pODC 934 plasmid containing 1.4 kb mouse ODC
cDNA insert was used as a probe. The protein con-
centration was estimated according to the method of
Lowry et al. [32]. The results are expressed as
means þ S.D.; the number of mice is given in paren-
theses. Data were statistically analyzed by the
Mann^Whitney test.
2.3. Chemicals
All chemicals purchased from commercial sources
were of analytical grade. Reserpine and apomorphine
were obtained from Sigma, phenylephrine (as Neo-
Synephrine) and isoproterenol (as Isuprel) were from
Winthrop USA and France, respectively. SKF 38393,
quinpirole, phenoxybenzamine, spiroperidol and
SCH 23390 were from RBI, USA. Propranolol was
from ICI, UK. Rediprime (Random Primer Label-
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ing), Hybond-N, Hyper¢lm-MP, [K-32P]dCTP (110
TBq/mmol) and DL-[1-14C]ornithine hydrochloride
(2.15 GBq/mmol) were obtained from Amersham,
UK. CB 3717 and casodex were generously provided
by Zeneca Pharmaceuticals, Alderly Park, Maccles-
¢eld, Cheshire, UK.
3. Results
3.1. E¡ect of reserpine on antifolate-induced ODC
gene expression and kidney hyperplasia
Catecholamine depletion, evoked by reserpine,
dramatically impaired the CB 3717-induced increase
of ODC activity characteristic for mouse kidney
undergoing hyperplasia (Fig. 1). Thus, in the pres-
ence of reserpine, administered 1 h before CB 3717,
the ODC activity reached less than 6% of the activity
induced by the antifolate alone. Depletion of endog-
enous catecholamines by reserpine persisted for sev-
eral days as evidenced by the weaker but still signi¢-
cant e¡ect of reserpine administered 96 h prior to CB
3717 (Fig. 1).
While depletion of catecholamines prevented ODC
induction by antifolate, the additional activation of
catecholamine receptors did not further increase anti-
folate-induced ODC activity. This was shown in ex-
periments with quinpirole (Fig. 1) and apomorphine
(data not shown), dopamine receptor agonists, that
induced ODC expression in normal kidney (compare
Section 3.3). It appears, therefore, that renal endog-
enous catecholamine levels were su⁄cient for the
maximal ODC activation in kidneys undergoing hy-
perplasia.
The spectacular increase of ODC activity in CB
3717-induced hyperplastic kidney was paralleled by
a nearly 3-fold, highly signi¢cant augmentation of
ODC mRNA levels; the result of a representative
experiment is shown in Fig. 2A. Catecholamine de-
pletion, produced by reserpine administered 1 h be-
fore CB 3717, lowered the ODC transcript level by at
least 60% (Fig. 2B). The increase of ODC mRNA
evoked by antifolate alone, and decrease by coad-
ministered reserpine and antifolate, although very
signi¢cant was, however, less pronounced than the
changes of ODC activity under the same conditions.
The CB 3717-induced enlargement of the kidneys
connected with regenerative hyperplasia of the in-
jured renal tubular epithelium was also a¡ected by
catecholamine depletion (Table 1). Thus, reserpine
given 1 h (but not 96 h) before CB 3717 prevented,
to some extent, drug-induced kidney enlargement,
the e¡ect being highly signi¢cant. This response of
kidney hyperplasia was in contrast to testosterone-
induced kidney hypertrophy which was insensitive to
reserpine treatment [2].
Fig. 1. The e¡ect of reserpine or quinpirole (10 mg/kg) on CB
3717-induced ODC activity. P values vs. CB 3717-treated mice
are: *P6 0.05; ***P6 0.001; NS, not signi¢cant.
Table 1
E¡ect of reserpine on kidney enlargement in CB 3717-treated mice
Treatment Relative kidney weight (% of the body weight) P value
Control 1.11 þ 0.09 (16)
CB 3717 2.03 þ 0.17 (13) ^
Reserpine 1 h before CB 3717 1.59 þ 0.19 (12) 6 0.0001
Reserpine 96 h before CB 3717 1.96 þ 0.29 (12) NS
P value was calculated vs. CB 3717-treated mice; NS, not signi¢cant.
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3.2. Attempts to identify catecholamine receptor(s)
involved in ODC induction in antifolate-evoked
hyperplastic kidney
The results obtained with reserpine, which evokes
catecholamine depletion, demonstrated the impor-
tance of these biogenic amines for ODC induction.
Several K, L and D receptor antagonists were used to
study the type of catecholamine receptor(s) that
could mediate the response of renal ODC to the
antifolate. None of the applied antagonists, exerted
a signi¢cant decrease on the ODC activity induced
by CB 3717 (Table 2). Similar, non-signi¢cant e¡ects
were observed when D1 and D2 receptor antagonists
were given simultaneously (Table 2), or a 10-times
higher amount of D1 receptor antagonist was ap-
plied (data not shown). It is to be noted that some
of the antagonists exerted slightly agonistic e¡ects in
accordance with two previous reports [20,33]. The
obtained results did not allow us, at present, to iden-
tify which catecholamine receptors are involved in
CB 3717-induced ODC expression. It appears that
other experimental schedules should be applied to
solve this problem.
3.3. E¡ect of catecholamine receptor agonists on
ODC expression in normal kidney
To evaluate the role of catecholamines in ODC
expression in normal kidney, the e¡ect of several
agonists of adrenergic and dopaminergic receptors
was examined. (Fig. 3). The low renal ODC activity
was not elevated by phenylephrine, an K1 adrenore-
ceptor agonist, while isoproterenol, which stimulates
L adrenoreceptors, caused a signi¢cant, 1.7-fold in-
crease of ODC activity. Apomorphine, acting mainly
as an agonist of D2 but also of D1 receptors, ap-
peared even more e¡ective as an ODC inducer. Thus,
stimulation of dopamine receptors by apomorphine
resulted in pronounced increase of ODC activity
(Fig. 3) and lower but signi¢cant rise in ODC tran-
script level (Fig. 2C). In experiments with the use of
Table 2
E¡ect of K, L, D1 and D2 receptor antagonists on CB 3717-induced ODC activity
Conditions ODC activity, % P value
CB 3717 100.0 þ 16.61 (13) ^
Phenoxybenzamine (K)+CB 3717 124.9 þ 24.0 (6) 6 0.05
Propranolol (L)+CB 3717 111.7 þ 21.7 (6) NS
SCH 23390 (D1)+CB 3717 100.1 þ 26.0 (7) NS
Spiroperidol (D2)+CB 3717 138.7 þ 20.6 (14) 6 0.001
SCH 23390 (D1)+spiroperidol (D2)+CB 3717 95.6 þ 13.9 (5) NS
Phenoxybenzamine (10 mg/kg) was injected twice: 1 h before and 11 h after CB 3717 (according to [20]). Propranolol (20 mg/kg) and
spiroperidol (1 mg/kg) were given 1 h before CB 3717. SCH 23390 (1 mg/kg) when administered alone was injected 24 h and 1 h be-
fore CB 3717. SCH 23390 (1 mg/kg) was coadministered with spiroperidol (1 mg/kg) and injected 1 h before CB 3717.
P value was calculated vs. CB 3717-treated mice; NS, not signi¢cant.
Fig. 2. The e¡ect of CB 3717 (A), reserpine plus CB 3717 (B)
and apomorphine (C) on renal ODC mRNA level as demon-
strated by Northern blot analysis. 18S and 28S rRNA ethidium
bromide-stained bands indicating the amount of RNA blotted
onto the ¢lter are shown below. Each lane represents RNA
from an individual mouse. Mean ODC mRNA relative val-
ues þ S.D. (the number of mice is given in parentheses) and P
values are as follows: CB 3717 (vs. control) 2.75 þ 1.34 (11),
P6 0.0001; (B) reserpine 1 h before CB 3717 (vs. CB 3717)
0.39 þ 0.26 (8), P6 0.001; (C) apomorphine (vs. control)
1.79 þ 0.48 (6), P6 0.05.
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selective D1 and D2 receptor agonists, SKF 38393
and quinpirole, respectively, it appeared that only
quinpirole signi¢cantly induced ODC activity while
SKF 38393 was without e¡ect (Fig. 3). These results
suggest that the D2, but not the D1, receptors are
implicated in ODC induction.
Transcriptional modulation of a target gene by
steroid hormones, androgens included, is mediated
by their nuclear receptors [23]. These ligand-depend-
ent transcription factors can sometimes be alterna-
tively activated by hydrophilic signaling substances,
among them by catecholamines, acting via their plas-
ma membrane receptors [4]. Thus, it could not be
excluded that in mouse kidney, an androgen-respon-
sive organ, the induction of ODC (testosterone target
gene) by catecholamines is mediated by an androgen
receptor. To verify this possibility an antiandrogen,
casodex, that dramatically impaired the testosterone-
induced ODC activity (to 12.8 þ 6.3%, n = 7,
P6 0.01) was applied. In contrast, this androgen re-
ceptor antagonist, when given before quinpirole (Fig.
4) or apomorphine did not prevent ODC induction,
its e¡ect being non-signi¢cant. Thus, catecholamine
control of ODC expression in normal kidney appears
to be an androgen receptor-independent process.
4. Discussion
In the present study two main problems were ad-
dressed. The ¢rst dealt with the participation of cat-
echolamines in antifolate-induced renal ODC expres-
sion and kidney hyperplasia. The second was
connected with the action of catecholamines as
ODC inducers in normal kidney.
Firstly, we showed that catecholamine depletion
produced by pretreatment of mice with reserpine pri-
or to antifolate administration drastically lowered
the ODC activity and ODC transcript level and
also prevented, to a signi¢cant extent, drug-induced
kidney hyperplasia. Thus, catecholamine- and antifo-
late-activated pathways, similarly to previously docu-
mented androgen and catecholamine cross-talk in
hypertrophic kidney [2], seem to interconnect with
one another and are both involved in the activation
of renal ODC expression. However, an additional
activation of dopamine receptors by administered
quinpirole or apomorphine did not further increase
the antifolate-induced ODC activity. It seems, there-
fore, that the endogenous dopamine pool is su⁄cient
to maximally induce ODC expression in hyperplastic
kidneys. The identity of the catecholamine receptor
involved in CB 3717-induced ODC expression is un-
clear because of a lack of a signi¢cant inhibitory
e¡ect of the applied catecholamine receptor antago-
nists at the level of this induction. One can speculate
that under the applied experimental conditions (dos-
Fig. 4. The e¡ect of antiandrogen casodex on quinpirole-in-
duced renal ODC activity. Casodex (40 mg/kg) was injected
twice: 22 h and 1 h before quinpirole (10 mg/kg) which was
given to the mice for 2 h. P value was calculated vs. quinpir-
ole-treated mice; NS, not signi¢cant.
Fig. 3. Catecholamine receptor agonists as inducers of ODC ac-
tivity in normal mouse kidneys. Phenylephrine (2.5 mg/kg) and
isoproterenol (1 mg/kg) were injected for 4 h; apomorphine (10
mg/kg) for 1 h; SKF 38393 (10 mg/kg) and quinpirole (10 mg/
kg) for 2 h. P values vs. control are: **P6 0.01; ***P6 0.001;
****P6 0.0001; NS, not signi¢cant.
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age and timing according to literature), antagonists
were unable to displace endogenous catecholamines
from their receptors and were therefore ine¡ective.
Hyperplastic and hypertrophic renal growth and
the role of ODC and polyamines in these processes
have been thoroughly studied in this laboratory
[1,2,14^17,34]. The signi¢cant decrease of antifo-
late-induced renal hyperplasia concomitant with a
dramatic fall of ODC expression in catecholamine-
depleted mice (this paper) con¢rms our previous data
on the sensitivity of renal hyperplastic growth to
ODC inhibition evoked by DFMO [1].The ODC de-
pendence of hyperplastic renal growth is in contrast
to hypertrophic growth independence of androgen-
induced ODC [1,2].
The signal transduction pathway activated in the
mouse kidney by CB 3717 treatment, which in con-
sequence leads to activation of ODC gene expression,
has not been investigated in the present study. We
hypothesize that an antifolate-evoked injury of epi-
thelial cells in renal proximal tubules may induce
proteolytic activation or increased expression of hep-
atocyte growth factor/scatter factor (HGF/SF), a po-
tent pleiotropic cytokine playing major roles in de-
velopment, regeneration and carcinogenesis [35].
HGF, among others, functions as a renotropic factor
for kidney regeneration following acute renal injuries
[36,37]. Our supposition is strengthened by recent
data which document the increased expression of
HGF and/or its membrane receptor in renal hyper-
plasia, acute renal injury evoked by HgCl2 treatment
and several di¡erent models of renal hypertrophy
[36^38]. Recently, in in vitro studies, the induced ex-
pression of ODC in HGF-treated normal and neo-
plastic hepatocytes has been documented [39,40].
Therefore, it is highly probable that HGF may also
trigger signaling pathway leading to induction of
ODC in vivo in antifolate-induced hyperplastic kid-
ney. This is at present under investigation.
Secondly, using several speci¢c agonists of adren-
ergic and dopamine receptors we documented the
ability of catecholamines to induce the ODC activity
in normal female mouse kidney. We showed that the
activation of dopamine receptors, in particular of the
D2 type, and to a lesser extent of L adrenoreceptors
stimulated the ODC activity severalfold concomitant
with a lower, but signi¢cant increase, in ODC
mRNA level. A higher induction degree of the
ODC activity than its transcript level by catechol-
amines (and also by CB 3717) may result from an
increased intracellular stability of induced ODC pro-
tein and its catalytic e⁄ciency due to enzyme protein
phosphorylation [41]
The identi¢cation of catecholamine receptors par-
ticipating in ODC induction in normal kidney is
based on the results of experiments with their selec-
tive agonists. The very low basal ODC activity in
female mouse kidney, together with the relatively
low catecholamine-evoked ODC induction and high
mouse to mouse variations, made it di⁄cult to use
the appropriate antagonists. In mouse kidney mainly
dopamine and to a smaller extent L receptors are
involved in the induction of ODC expression (this
paper). This is in contrast to adrenergic, but not
dopaminic, control of ODC activity (mainly through
L-adrenergic receptors linked to the adenylate cyclase
system) documented in several cells and tissues [42^
46]. These results point to catecholamine receptor
tissue speci¢city in the regulation of ODC expression
and a critical role of dopamine in kidneys.
In the rodent kidney, dopamine is an abundant
neurotransmitter being either of neuronal origin or
biosynthesized intrarenally mainly in apical poles of
proximal tubular cells [47,48]. In this organ, dopa-
mine exerts a variety of physiological actions due to
activation of two main types of receptors, D1 and
D2 [49]. In our studies we show that D2 receptors,
and to a smaller extent L adrenoreceptors, mediate
the catecholamine activating e¡ect on ODC gene ex-
pression in normal kidneys. In this context it is note-
worthy that D2 receptors colocalize in renal proxi-
mal tubules with ODC gene transcript [50,51]. The
stimulation of D2 receptors coupled to many distinct
signaling pathways results, among others, in the in-
hibition of adenylate cyclase activity and in an in-
crease in intracellular calcium levels (via phospholi-
pase C activation). L receptors, in contrast to D2
receptors, mediate the activation of adenylate cyclase
and the opening of plasma membrane calcium chan-
nels. It is to be noted, therefore, that, while D2 and L
receptor activation di¡erentially a¡ects the cAMP
generating system, in both cases it results in calcium
level increases. In this context a suggestion for the
calcium mediation of catecholamine-induced proc-
esses involved in ODC gene expression in regenerat-
ing liver [52] appears to be signi¢cant.
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Recently it has been established that some steroid
receptors can be alternatively activated in the ab-
sence of their lipophilic ligands by a variety of ex-
tracellular signals, catecholamines included [3^5,25].
In rat hypothalamus dopamine acting through its D1
receptors was shown to activate the progesterone re-
ceptor in a ligand-independent manner and thus reg-
ulate gene expression [53]. However, in mouse kid-
ney, an androgen responsive organ, the
catecholamine-evoked induction of ODC expression,
mediated mainly by D2 receptors, appears to be in-
sensitive to an antiandrogen - casodex, suggesting
that it occurs via an androgen receptor-independent
pathway. Whether this catecholamine-mediated path-
way depends on a coactivator and integrator CBP
(CREB-binding protein), an important point of con-
vergence for many signaling pathways [6,7,22], re-
mains to be shown. It should also be considered
that catecholamine induction of ODC gene expres-
sion may be secondary and connected with the tran-
scriptional activation of catecholamine-dependent
regulatory protein, which in turn a¡ects ODC ex-
pression.
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